Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acumen Pharmaceuticals Inc
NASDAQ ABOS
Data sourced from
and
and
Acumen Pharmaceuticals Inc Sales to Working Capital Ratio for the year ending December 31, 2023: 0.00
Acumen Pharmaceuticals Inc Sales to Working Capital Ratio is 0.00 for the year ending December 31, 2023, a 0.00% change year over year. The sales to working capital ratio measures the revenue generated by a company relative to its working capital. It is calculated by dividing the revenue by the difference between current assets and current liabilities. This ratio indicates the company's revenue generation efficiency based on its working capital. A higher sales to working capital ratio suggests better utilization of working capital to generate sales revenue.
-
Acumen Pharmaceuticals Inc Sales to Working Capital Ratio for the year ending December 31, 2022 was 0.00, a -100.00% change year over year.
-
Acumen Pharmaceuticals Inc Sales to Working Capital Ratio for the year ending December 31, 2021 was 0.01, a -80.33% change year over year.
-
Acumen Pharmaceuticals Inc Sales to Working Capital Ratio for the year ending December 31, 2020 was 0.04, a -87.03% change year over year.
-
Acumen Pharmaceuticals Inc Sales to Working Capital Ratio for the year ending December 31, 2019 was 0.29.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ABOS
| CEO | Mr. Daniel J. O'Connell M.B.A. |
| IPO Date | July 1, 2021 |
| Location | United States |
| Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email